Lineage Cell Therapeutics Receives CE Mark Approval for Renevia®

Go back to Lineage Cell Therapeutics Receives CE Mark Approval for Renevia®
(NYSE: LCTX) Delayed: 1.00 +0.01 (1.01%)
Previous Close $0.99    52 Week High $ 
Open $0.97    52 Week Low $ 
Day High $1.02    P/E N/A 
Day Low $0.94    EPS $ 
Volume 1,150,210       

(NYSE: LCTX) Delayed: 1.00 +0.01 (1.01%)
Previous Close $0.99    52 Week High $ 
Open $0.97    52 Week Low $ 
Day High $1.02    P/E N/A 
Day Low $0.94    EPS $ 
Volume 1,150,210